Please assess the completion status of the following clinical trial:

Trial Title: Effect of Low-dose Intracoronary Reteplase on Myocardial Infarct Size During Primary Percutaneous Coronary Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Acute STEMI with persistent ST-segment elevation or recent left bundle-branch block with a symptom onset to reperfusion time of 12 hours or less.~2. Angiographic criteria included a proximal-mid coronary artery occlusion (TIMI coronary flow grade 0 or 1) or, impaired coronary flow (TIMI flow grade 2, slow but complete filling) in the presence of definite angiographic evidence of large thrombus (TIMI grade ≥2) in left anterior descending (LAD) coronary artery.~Exclusion Criteria:~1. Rescue PCI after thrombolytic therapy.~2. Need for emergency coronary artery bypass grafting.~3. Presence of cardiogenic shock.~4. Life expectancy of \< 6 months.~5. Inability to provide informed consent.~6. Contraindications for the use of thrombolysis, including active internal bleeding, history of intracranial haemorrhage or ischaemic stroke within 6 months, recent major surgery or trauma, severe uncontrolled hypertension, thrombocytopenia and severe liver or kidney failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): intracoronary infusion with saline
- reteplase 9mg (Type: EXPERIMENTAL): intracoronary infusion with reteplase 9mg
- reteplase 18mg (Type: EXPERIMENTAL): intracoronary infusion with reteplase 18mg

Based on this trial design, predict the completion outcome and termination type (if applicable).